Leveraging RetinAI’s Discovery® platform and AI tools will enable Eyestem to advance in its mission to revolutionise treatment for geographic atrophy with its innovative cell therapy, Eyecyte-RPE™.
“This collaboration with RetinAI marks a significant milestone in our journey,” said Dr Jogin Desai, Founder and CEO of Eyestem. “Their sophisticated AI tools and the RetinAI Discovery® platform integrate perfectly with our vision, potentially shortening the timelines for our clinical trials and enhancing the accuracy of our analyses. This is not just a partnership; it’s a confluence of high-end biotech innovation and cutting-edge artificial intelligence aiming to rewrite the narrative for patients affected by geographic atrophy worldwide.”
Dr. Carlos Ciller, CEO of RetinAI, expressed his enthusiasm about the collaboration: “We are excited to partner with Eyestem, known for its forward-thinking approach to biotechnology and cell therapy. Our AI-driven Discovery® platform is poised to significantly accelerate research and provide enhanced insights into disease progression and outcomes. Together, we’re confident that this synergy will not only enrich insights in the development of novel treatments but also manifest in delivering life-altering solutions faster to individuals affected by retinal diseases globally.”
Geographic atrophy, a late-stage form of dry age-related macular degeneration (AMD), is a significant health concern worldwide. Currently, dry AMD affects 200 million individuals globally, contributing to irreversible vision loss. Compounded by an aging population, the prevalence of this serious eye disease is escalating at an alarming rate.
Eyestem is taking a significant step forward by preparing to initiate its Phase I/IIa clinical trials for Eyecyte-RPE™. This multi-centre, dose escalation, and expansion trial aims to assess Eyecyte-RPE™’s safety and efficacy for geographic atrophy. This trial will benefit from RetinAI’s Discovery® platform, which will centralise data management and image analysis for the study. Moreover, RetinAI’s advanced segmentation model will be leveraged for the identification and quantification of retinal biomarkers in geographic atrophy. This automated analysis will provide real-time insights on clinical endpoints, speeding up critical decision-making.
About RetinAI
Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI US Inc., are transforming clinical and pharmaceutical research with cutting-edge machine learning and computer vision. Their collaboration with healthcare experts enhances data analysis for improved research and clinical trials. RetinAI's platform's extensive list of AI models, including for major ophthalmic disorders like Geographic Atrophy, enable detailed analysis of large datasets, offering critical insights into patient demographics and biomarker profiles. This innovation not only expedites informed decision-making but also shifts the healthcare paradigm from reactive to proactive. Discover more of the solutions for pharma here: https://www.retinai.com/solutions/life-sciences-pharma and on their website: www.retinai.com.
About Eyestem
Based in Bangalore and Delaware, Eyestem Research is a clinical-stage biotech company founded by an experienced team in pharmaceuticals, ophthalmology, and cell biology. It's recognised as a top innovator nationwide, earning accolades from Economic Times in 2022. Eyestem has received grants from the Indian Department of Biotechnology and has been celebrated as a successful startup at government events. Backed by global investors, including Switzerland and South Africa, it's supported by prestigious venture capital firms Kotak Investment Advisors and Endiya Partners. Its recent funding came from three major Indian pharmaceutical companies: Alkem Laboratories, NATCO, and Biological E.
Advertisements